Leprosy Diagnostic Test Development As a Prerequisite Towards Elimination: Requirements from the User’s Perspective

• Edith Roset Bahmanyar,

  Affiliation Novartis Foundation, Novartis Campus, Basel, Switzerland

  ⨯
• William Cairns Smith ,

  * E-mail: w.c.s.smith@abdn.ac.uk

  Affiliation School of Medicine, University of Aberdeen, Aberdeen, Scotland, United Kingdom

  ⨯
• Patrick Brennan,

  Affiliation Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, United States of America

  ⨯
• Ray Cummings,

  Affiliation PATH, Seattle, Washington, United States of America

  ⨯
• Malcolm Duthie,

  Affiliation Infectious Disease Research Institute, Seattle, Washington, United States of America

  ⨯
• Jan Hendrik Richardus,

  Affiliation Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

  ⨯
• Paul Saunderson,

  Affiliation American Leprosy Missions, Greenville, South Carolina, United States of America

  ⨯
• Tin Shwe,

  Affiliation American Leprosy Missions, Yangon, Myanmar

  ⨯
• Steven Rosen,

  Affiliation Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America

  ⨯
• Annemieke Geluk

  Affiliation Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands

  ⨯